Autonomix Medical to Execute 1-for-21 Reverse Stock Split — Autonomix Medical, Inc.

Event summary

Autonomix Medical will execute a 1-for-21 reverse stock split effective June 24, 2026.
Outstanding shares will reduce from ~11.4 million to ~543,000 post-split.
Trading will resume under the same ticker (AMIX) but with a new CUSIP number.
No fractional shares will be issued; cash payments will be made instead.

The big picture

Reverse stock splits are often a last-resort measure to avoid delisting or boost share price, but Autonomix's move—one of the most aggressive splits in recent memory—suggests deeper capital structure concerns. The company's focus on nerve-targeted treatments for conditions like pancreatic cancer pain positions it in a niche but competitive medical device sector, where regulatory and reimbursement hurdles remain high.

What we're watching

Market Perception: How investors will react to the reduced share count and potential liquidity impact.
Regulatory Compliance: Whether the SEC will scrutinize the timing or execution of the reverse split.
Strategic Intent: If this move signals broader financial restructuring efforts amid clinical development costs.